beta
Trial Radar AI
One study matched filter criteria
Card View
Back to Search

Assess Impact of Poly-L-lactic Acid on GLP1 Subjects Phase 2 20

Not yet recruiting
Clinical Trial NCT07217743 is designed to study Treatment for Laxity; Skin. This Phase 2 interventional study is not yet recruiting. Enrollment is planned to begin on 27 October 2025 until the study accrues 20 participants. Led by Goldman, Butterwick, Fitzpatrick and Groff, this study is expected to complete by 31 October 2026. The latest data from ClinicalTrials.gov was last updated on 16 October 2025.
Brief Summary
Clinical trial to evaluate treatments of double-dilute poly-L-lactic acid on abdominal skin laxity in GLP1 patients versus non GLP1 patients.
Detailed Description
20 patients total (15 GLP1 and 5 non-GLP1) will receive three treatments of double-dilute PLLA (Sculptra® Aesthetic; Galderma Laboratories; Fort Worth, TX) to the abdomen one month apart. Using a 22 G 2" cannula, up to 16cc of poly-L-lactic acid will be used per treatment. Patients will return for follow up visits at month 3 and month 9, where they will undergo standardized 2D photography and assessments.
Official Title

Prospective, Single Center, Open-label Study Assessing Impact of Poly-L-lactic Acid on Adipogenesis in Patients on Glucagon-like Peptide-1 Agonists

Conditions
Laxity; Skin
Other Study IDs
  • Sculptra-Aesthetic-GLP1
NCT ID Number
NCT07217743
Start Date (Actual)
2025-10-27
Last Update Posted
2025-10-16
Completion Date (Estimated)
2026-10-31
Enrollment (Estimated)
20
Study Type
Interventional
PHASE
Phase 2
Status
Not yet recruiting
Keywords
laxity
loose skin
glp1
abdominal laxity
Primary Purpose
Treatment
Design Allocation
Non-Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Active ComparatorGLP1 Patients
15 Participants who have been on a stable dose of GLP1 for at least 6 months will receive three treatments, one month apart, of Sculptra Aesthetic up to 16cc.
Sculptra Aesthetic
15 GLP1 subjects treated with Sculptra to their abdomen for skin laxity will be compared to 5 non GLP1 subjects treated with Sculptra for skin laxity.
ExperimentalNON GLP1 Patients
5 participants who are GLP1 naive will receive three treatments, one month apart, of Sculptra Aesthetic up to 16cc.
Sculptra Aesthetic
15 GLP1 subjects treated with Sculptra to their abdomen for skin laxity will be compared to 5 non GLP1 subjects treated with Sculptra for skin laxity.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Physical Global Aesthetic Improvement Scale
Assess improvement of Abdominal skin laxity: Much Improved 2 Improved 1 No Change 0 Worse -1 Much Worse -2
Month 3 and Month 9
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Subject Global Aesthetic Improvement Scale
Assess improvement of Abdominal skin laxity: Much Improved 2 Improved 1 No Change 0 Worse -1 Much Worse -2
Month 3 and Month 9
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
25 Years
Eligible Sexes
Female
Accepts Healthy Volunteers
Yes

  1. Adult women aged 25-65 years.

  2. Fitzpatrick skin types I-IV.

  3. Presence of mild to moderate skin laxity of abdomen, as determined by clinical investigators.

  4. Stable weight for 3 months, with body mass index (BMI) of 27 or less.

  5. Current treatment with a stable dose of GLP-1 agonist medication for at least the last 6 months, for 15 of the enrolled subjects. Remaining 5 subjects should not be taking or have a history of taking a GLP-1 agonist medication, and should not be planning to take a GLP-1 in the foreseeable future.

  6. Must be willing to sign a photography release and ICF, and complete the entire course of the study.

  7. Subjects in good general health based on investigator's judgment and medical history.

  8. Negative urine pregnancy test result at the time of study entry (if applicable).

  9. Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.

    1. Acceptable forms of birth control are: oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device/coil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and/or vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.
    2. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and/or both ovaries (oophorectomy), or bilateral tubal ligation.

  1. The presence of severe abdominal skin laxity as determined by clinical investigators.
  2. Still actively losing weight.
  3. Pregnancy or planned pregnancy during the study or currently breastfeeding.
  4. Any uncontrolled systemic disease.
  5. History of autoimmune connective tissue disease.
  6. Current use of immunosuppressive medication.
  7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
  8. Active dermatitis or active infection in the proposed treatment area.
  9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.
  10. Any investigational treatment for skin quality of the abdomen during the 12-month period before the study treatment
  11. Creams/cosmeceuticals and/or home therapies for the prevention or treatment of skin quality in the treatment area during the 1-month period before study treatment
  12. Subjects with scarring in the treatment areas, including laparoscopic or abdominal surgery scars, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.
  13. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.
  14. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and/or current pregnancy or breastfeeding .
  15. Inability to ambulate following the procedure.
  16. History of lidocaine and/or epinephrine sensitivity deemed by the investigator to preclude subject from enrolling into study.
  17. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.
  18. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
Goldman, Butterwick, Fitzpatrick and Groff logoGoldman, Butterwick, Fitzpatrick and Groff
Study Central Contact
Contact: Andrea Pacheco, 858-657-1004, [email protected]
1 Study Locations in 1 Countries

California

West Dermatology Research Center, San Diego, California, 92121, United States
Andrea Pacheco, Contact, 858-657-1004, [email protected]
Freia Canals-Cistero, Contact, 858-657-1004, [email protected]